New this month, from Chamow & Associates’ Jennifer Bratt, Angela Linderholm, Bryan Monroe and Steven Chamow, is a review on bispecific antibodies (bsAbs) published in BioProcess International titled “Therapeutic IgG-like…
One of the first tasks necessary for recombinant production of a protein or mAb is synthesis of cDNA(s) that will encode the protein of interest. This is typically done by…
We often blog about monoclonal antibodies and the increasingly important role of this drug class in modern medicine. Monoclonal antibodies were first made possible with the development of hybridoma technology…
Until a few years ago, millions of American gout sufferers could buy colchicine, a long-established prescription drug to treat the painful ailment, for about $0.09 a pill. But in 2010,…
Success in targeted delivery of therapeutics often relies on formulation. The ability to get biomolecules to where they are needed and taken in by the correct cell types requires strategic…
Multiple Myeloma (MM) is a plasma cell malignancy that accounts for approximately 1% of all cancers. The disease often involves bone and kidney, causing morbidity from pathological fractures, bone pain,…
Monoclonal antibodies (mAbs) are remarkable proteins. Representing more than 50 FDA approved products for a variety medical indications, mAbs are the fastest growing class of new biologics today. Produced naturally…
The field of immuno-oncology has rapidly expanded since the 2011 approval of ipilimumab, the first monoclonal antibody that acts as an immune checkpoint inhibitor and is effective in treating cancer. The predicted…
Precision medicine is the cutting edge of diagnosis and treatment; it encompasses medical practices and products that are tailored to individual patients. Aligned with that is the development of novel…
In October/November 2014, we published a pair of articles in Bioprocess International that examined how the potential therapeutic value of many proteins — including enzymes, receptors, cytokines, blood factors and…